CollPlant Biotechnologies Evaluates 3D-Bioprinted Regenerative Breast Implants in Preclinical Study

Regenerative and aesthetics medicine company, CollPlant Biotechnologies (Nasdaq: CLGN) has initiated a preclinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. There is currently no commercially-available product that allows regeneration of soft tissues, such as the breast.

Yehiel Tal, CollPlant’s Chief Executive Officer, commented on the company’s progress. “We are very happy with the progress of our regenerative breast implants program thus far, and the initiation of this important study. This would be paradigm-shifting in a market that has maintained such a large demand yet has seen increasing issues with safety over the last few decades. A primary goal of this study is to obtain data which would then support the optimization of the implant design and apply this design to a pivotal large-animal study that is intended to be the subject of discussions with the FDA.”

Mr. Tal described CollPlant’s breast implants as unique, having been designed to regenerate breast tissue, and with inherent safety advantages.

A University of Alberta study found that as many as 26% of women who get silicone breast implants are likely to develop an autoimmune disease. A small number go on to develop breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare type of non-Hodgkin’s lymphoma associated with breast implants. CollPlant’s breast implants, comprised of the Company’s proprietary plant-derived rhCollagen and other biomaterials, are expected to regenerate breast tissue without eliciting immune response and therefore may provide a revolutionary alternative for aesthetic and reconstructive procedures.

In January 2023, CollPlant announced positive results from its first large-animal study, which demonstrated progressive stages of tissue regeneration after three months, and no adverse events. CollPlant expects the current study to conclude by the first half of 2024.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company’s products are based on its rhCollagen (recombinant human collagen) produced with CollPlant’s proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.